Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.5. rezultāts no 100.
25. lappuse
... addition to the information speci- fied in §314.50 of this chapter , the appli- cation shall contain : ( i ) A full list of the articles used as components of the digoxin product , specifications for components , detailed identification ...
... addition to the information speci- fied in §314.50 of this chapter , the appli- cation shall contain : ( i ) A full list of the articles used as components of the digoxin product , specifications for components , detailed identification ...
71. lappuse
... addition or dropping of a control group ) . ( iii ) The addition of a new test or procedure that is intended to improve monitoring for , or reduce the risk of , a side effect or adverse event ; or the dropping of a test intended to ...
... addition or dropping of a control group ) . ( iii ) The addition of a new test or procedure that is intended to improve monitoring for , or reduce the risk of , a side effect or adverse event ; or the dropping of a test intended to ...
268. lappuse
... addition to the warn- ings in §349.50 , the labeling of the prod- uct contains the following warnings under the heading " Warnings " for products containing any ingredient identified in § 349.12 : ( 1 ) " If you experience eye pain ...
... addition to the warn- ings in §349.50 , the labeling of the prod- uct contains the following warnings under the heading " Warnings " for products containing any ingredient identified in § 349.12 : ( 1 ) " If you experience eye pain ...
297. lappuse
... addition to the above warning , the label of a drug packaged in a self - pres- surized container in which the propel- lant consists in whole or in part of a halocarbon or hydrocarbon shall bear the following warning : Warning - Use only ...
... addition to the above warning , the label of a drug packaged in a self - pres- surized container in which the propel- lant consists in whole or in part of a halocarbon or hydrocarbon shall bear the following warning : Warning - Use only ...
301. lappuse
... addition to the in- formation required by paragraphs ( a ) , ( b ) , and ( c ) or ( i ) of this section ) , a cau- tion against use if the drug has become viscous or if its color has become other than water clear . ( e ) On the outside ...
... addition to the in- formation required by paragraphs ( a ) , ( b ) , and ( c ) or ( i ) of this section ) , a cau- tion against use if the drug has become viscous or if its color has become other than water clear . ( e ) On the outside ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning